does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. Am. J. Physiol. 258 (Endocrinol. Metab. 21): El58E162, 1990.-Increased circulating levels of 1,25dihydroxyvitamin D [ l,25(OH)zD] during pregnancy could be due to an increase in production or decrease in the metabolic clearance rate of 1,25(OH)zD. To answer this question an isotope dilution method was used to determine the clearance rate of 1,25( OH)2D in pregnant and aged-matched nonpregnant female rats. A bolus of 0.146 &i l,25(OH)2[3H]D3 was given to 60 pregnant and 60 aged-matched nonpregnant rats and the disappearance of the isotope was followed in these animals over the next 48 h. In 12 pregnant rats vs. 14 nonpregnant controls not injected with tracer, plasma calcium (9.6 t 0.41 vs. 10.7 t 0.17 mg/ml) and 25(OH)D (17.1 t 1.15 vs. 25.4 t 1.58 rig/ml) levels were significantly lower (P < 0.01 and P < O.OOl), whereas plasma 1,25(OH)zD levels (110 t 16.1 pg/ml vs. 77 & 6.0 pg/ml) were significantly higher (P < 0.05). Clearance rates of 1,25(OH)gD of 25.8 -t 1.31 pl/min in pregnant rats and 20.2 $-1.38 pl/min in nonpregnant aged-matched rats were not significantly different. Similarly, the apparent volume of distribution of 1,25(OH)zD in the pregnant rats (15 2 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 t 2.1 ml). Production rates of l,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min). In conclusion, the elevated maternal plasma l,25(OH)2D level during pregnancy is a result of increased production and is not due to a decreased clearance. (1-hydroxylase), the sole site for 1,25(OH)gD synthesis in the nonpregnant animal, is stimulated by parathyroid hormone and low plasma concentrations of calcium and phosphorus (4). In the pregnant animal the l-hydroxylase is also present in the fetal kidney (16, 30) and placenta (32).
(1-hydroxylase), the sole site for 1,25(OH)gD synthesis in the nonpregnant animal, is stimulated by parathyroid hormone and low plasma concentrations of calcium and phosphorus (4). In the pregnant animal the l-hydroxylase is also present in the fetal kidney (16, 30) and placenta (32) .
During pregnancy the mineral requirements for fetal bone growth cause net transfer of calcium from mother to fetus. This large efflux of maternal calcium stores contributes, in part, to the decline in maternal calcium levels (28) . The mother adjusts to the drain on her calcium supplies with an increase in fractional intestinal calcium absorption (14) . A considerable body of evidence suggests that 1,25(OH)gD is responsible, in part, for this increase in intestinal calcium absorption during pregnancy. Maternal plasma 1,25(OH)zD levels are elevated during pregnancy in both women (17,31) and laboratory animals (12, 16, 25) . Vitamin D deficiency eliminates the majority of the increase in intestinal calcium transport during pregnancy (13). Inadequate supplies of vitamin D during pregnancy can result in maternal osteomalacia and neonatal rickets and hypocalcemia (22) .
The mechanism behind the increase in maternal plasma 1,25( OH)2D concentrations during pregnancy is not known but could be a result of an increase in the production or a decrease in the elimination of the hormone. The elevated 1,25(OH)2D levels of pregnancy could also be secondary to the increase in plasma vitamin D binding protein (1, 2). The present report shows that the increase of maternal plasma 1,25(OH)2D levels during pregnancy is due to an increase in the production rate without a significant change in the elimination rate of 1,25(OH)2D.
METHODS
Vitamin D compounds. 1,25-(OH)2[26,27-3H]D3 with a specific activity of 157 Ci/mmol was purchased from Amersham (Arlington Heights, IL). The purity of the [3H]1,25(OH)2D3 was found to be 92% as determined by straight-phase high-performance liquid chromatography (Varian model 5000, Varian Industries, Palo Alto, CA) on a 4.6 mm X 25 cm Zorbax SIL column (Du Pont Industries, Wilmington, DE) using isopropanol-hexane (5:95, vol/vol) at 2 ml/min as the eluting solvent. The 1,25(OH)2D3 was kindly supplied by Dr. Milan Uskokovic (Hoffmann-La Roche, Nutley, NJ).
Animals. Seventy-two sperm-positive rats at day 6 of gestation and 74 aged-matched female rats were obtained from Holtzman (Madison, WI). Two days after arrival, animals were given deionized distilled water and placed, ad libitum, on a nutritionally complete diet containing 0.6% calcium, 0.6% phosphorus, and 2.2 IU vitamin D3/ gm diet (Teklad, Madison, WI). After 11 days, 60 of the pregnant and 60 of the aged-matched control rats were randomly placed in 12 groups of five animals each for were collected, air dried, and radioactivity determined by scintillation spectrophotometry with a Beckman model L5350 liquid scintillation counter (Palo Alto, CA). Recovery of 1,25(OH)2[3H]D3 was determined by quantitating the remainder of the added 100 ng of authentic 1,25(OH)2D3 by radioreceptor binding assay utilizing the 100,000 g binding protein from bovine thymus cytosol (27) . Because large dilution of sample is necessary to measure the recovered cold 1,25(OH)zD3 previously added, there is no interference with the binding assay by the serum concentration of injected tracer 1,25(OH)2D3. After correction for recovery, data were expressed as disintegrations per minute per milliliter. where C is concentration of tracer in the pool, Co is concentration of tracer in the pool at time 0 in disintegrations per minute per milliliter, HI and H2 are coefficients that define the starting point of the curve, k1 and ka are rate constants of removal, and t is time. The area under the tracer concentration vs. time curve was determined (29 Calcium was measured in triplicate by fluorometric titration (Calcette, Precision Instruments, Natick, MA). Plasma phosphorus was determined in duplicate according to the method of Fiske and SubbaRow (10).
Assay of parathyroid hormone (PTH). Plasma PTH was assayed using a rat mid-molecule PTH radioimmunoassay (Incstar Corporation, Stillwater, MN) as previously described ( 18) .
Statistical analysis. The tracer concentration vs. time curves for the pregnant and control rats were compared using analysis of variance for repeated measures. The differences of the serum biochemistries between the two groups was determined using a one-tailed Student's t test. All analyses were performed by computer-assisted methodologies (MK Model, Biosoft, Cambridge, UK; BMDP, University of California, Berkeley, CA). P values of 0.05 or greater were chosen to denote significance. Table 1 . Pregnancy resulted in an expected increase in body weight. The body weights of the pregnant and aged-matched nonpregnant rats that received radiotracer 1,25(OH)2[3H]D3 (Table 2) were not significantly different from the body weights of their counterparts described in Table 1 . Pregnant animals had lower serum levels of Ca and 25(OH)D but a significantly higher serum level of 1,25(OH)2D. Plasma PTH levels were significantly higher in the pregnant rats vs. the nonpregnant controls. Serum P concentration was not altered by pregnancy. D3 from serum in both of these groups was biphasic and thus fit to the biexponential equation described in the METHODS section. The tracer concentration vs. time curves for the pregnant and the nonpregnant aged-matched control animals was found to be the same by analysis of variance for repeated measures (F = 3.92, P = NS). Table 2 presents the 1,25(OH)2D apparent (V,), clearance rate, and production rate 1,25(OH)zD determined from the data in Fig. 1 . The clearance rate and Vd of 1,25(OH)zD were the same in pregnant and aged-matched control female rats. The production rate of 1,25(OH)zD was higher in pregnant vs. aged-matched control female rats as indicated by the significantly higher serum 1,25(OH)zD levels and similar 1,25(OH)sD clearance rates. Table 2 ). t Significantly different from controls P < 0.001. $ Significantly different from controls P < 0.01. !$ Significantly different from controls P < 0.05. 
DISCUSSION
Vitamin D helps maintain calcium homeostasis and bony metabolism of the mother and newborn during pregnancy. Inadequate supplies of vitamin D during pregnancy can result in maternal osteomalacia and neonatal hypocalcemia (22) . This is especially prevalent in geographic locations where sunlight is restricted (2, 23) and in cultures where clothing reduces the exposure to the sun (23) . In diabetic pregnancy, maternal l,25(OH)2D levels are decreased (20, 34) , and infants from diabetic mothers have a high incidence of hypocalcemia (33) and reduced bone mineral content (19) . Because of the importance of 1,25(OH)2D to normal calcium homeostasis in mothers and newborns, we determined the production and clearance rates of 1,25(OH)zD in the pregnant rat.
It is well known that the maternal plasma 1,25(OH)zD levels increase during pregnancy in both women (l7,31) and laboratory animals (12, 16, 25). Similar results were obtained in the present study. The mechanism(s) responsible for this increase is (are) not known. Elevated maternal plasma l,25(OH)2D levels during pregnancy could be a result of one, or a combination of, the following possibilities: I) an increase in maternal kidney l-hydroxylase activity above nonpregnancy levels, 2) the presence of placental and/or fetal kidney l-hydroxylase activity, 3) a secondary effect due to the increase in the plasma concentration of the vitamin D binding protein (DBP), or 4) a decrease in the plasma elimination rate of l,25(OH)2D. The results of the present study indicate that the elevated l,25(OH)2D levels characteristic of pregnancy are due to an increased production of l,25(OH)2D and not secondary to a decrease in the metabolic clearance rate of the hormone. Similar findings have been reported in the rabbit (6).
The source of the elevated l-hydroxylase activity during pregnancy is not known but could be from the lhydroxylase present in the maternal kidney, fetal kidney, or placenta (23) . The kidney is generally recognized as the unique source of 1-hydroxylase activity in the nonpregnant animal (26) . However, in the pregnant animal, in vitro production of 1,25(OH)zD occurs also in the fetal kidney and placenta. Fetal l-hydroxylase activity has been found in rabbit (16), guinea pig (9), pig (30) , and rat kidney (32) . Placental I-hydroxylase activity has been observed in a number of species, including vitamin D-depleted rats (32) , guinea pig (9), and humans (5, 36) but not in rabbits (16) maternal kidney 1-hydroxylase activity may also be the source of the elevated maternal 1,25(OH)2D levels in the pregnant animal. Low plasma calcium levels, characteristic of pregnancy, acting directly or through PTH, may increase maternal kidney 1-hydroxylase activity. In support of this latter hypothesis, we found PTH levels to be elevated in the pregnant rats. It is possible that the high levels of 1,25(OH)zD during pregnancy are due entirely to an elevation in plasma DBP concentration, and increased 1-hydroxylase activity is not required to maintain the elevated plasma hormone concentration. Increased binding of 1,25(OH)2D to its specific carrier protein may protect the hormone from catabolism and result in a prolonged clearance rate and elevated plasma levels. Even though plasma levels of DBP are increased during pregnancy (1, 2) and with estrogen therapy (2), the present results show that pregnancy does not prolong the clearance rate of 1,25(OH)zD. Therefore, it seems unlikely that the elevation of DBP alone can explain the increased 1,25(OH)zD levels that we saw during pregnancy.
In the present study we used an isotope dilution method to determine maternal 1,25(OH)2D turnover rate. It should be recognized that the 1,25(OH)2D turnover rate in the pregnant animal, as determined by the present methodology, represents not only maternal utilization but also hormone transfer to the fetal-placental unit. Because we find the clearance rate of 1,25(OH)2D to be the same in pregnant as in nonpregnant agedmatched animals, hormone transfer to the fetal-placental unit must represent an insignificantly small percentage of maternal 1,25( OH)2D turnover. Therefore, maternal 1,25(OH)zD turnover rate as determined in this study is synonymous with maternal 1,25(OH)2D utilization.
The present study also provides valuable data concerning the pharmacokinetics of 1,25(0H)2D during pregnancy. We find the apparent Vd of 1,25(OH)2D in the pregnant animal to be similar to that of nonpregnant controls. This indicates that only a very small percentage of maternal 1,25(OH)zD is lost to the fetal compartment. However, our data do not indicate that the maternal contribution to fetal 1,25(OH)2D levels is insignificant. Because the fetal compartment is small compared with that of the mother, a minimal contribution by the mother to fetal 1,25(OH)zD metabolism may represent a large percentage to the fetus. Currently, the maternal contribution to fetal 1,25(OH)zD metabolism is unsettled. Previous studies have shown maternal plasma l,25(OH)2D levels not to correlate with fetal levels of the hormone (7,24,31), indicating that the mother does not influence fetal 1,25(OH)2D metabolism. However, a few studies (15, 35) show opposite results. One study used radiolabeled 1,25(OH)2D3 to show that 1,25(OH)zD crosses the placenta (21) , but this study was not quantitative in design.
The serum calcium and 25(OH)D levels were decreased in the pregnant rats in the present study. Low maternal plasma calcium, phosphorus, and 25(OH)D levels are characteristic of pregnancy (23, 28) , although we found no difference in serum phosphorus between pregnant and nonpregnant control animals. Increased substrate utilization by 1 -hydroxylases during pregnancy is thought to be responsible for the decreased 25(OH)D levels of pregnancy, consistent with our demonstration of increased 1,25( OH)2D turnover in pregnancy.
In summary, we find the elevated serum 1,25(OH)zD levels observed in the pregnant mother to be a result of an increase in production rate and not due to a decrease in the clearance rate of the hormone. Maternal 1,25(OH)2D flux to the fetal-placental unit represents a small percentage of maternal 1,25(OH)2D turnover rate.
